Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation

Allan Roza, Stephen Tomlanovich, Robert Merion, Raymond Pollak, Francis Wright, P. Rajagopalan, Timothy Pruett, John Scandling, Joan Ryan, Walid Awni, Sarah Schweitzer, Renee Greco, Wayne Lam, Azmi Nabulsi, Rebecca Hoffman

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Background. Gengraf capsule, an AB-rated generic cyclosporine for Neoral, has been shown to be bioequivalent in previous studies. The purpose of this pharmacokinetic study performed in stable renal transplant recipients was to evaluate interchangeability of Gengraf and Neoral. Methods. Using an open-label, three-period design, 50 renal transplant recipients taking stable doses of Neoral completed a multicenter study. Subjects continued their Neoral regimen during period I (days 1-14). Subjects then switched from Neoral on a milligram-for-milligram basis to Gengraf during period II (days 15-28), followed by conversion to the same milligram-for-milligram dosing regimen of Neoral during period III (days 29-35). Twelve-hour pharmacokinetic evaluations (maximum observed blood concentration [Cmax], concentration before dosing [Ctrough], time to maximum observed concentration [Tmax], and area under the blood concentration-vs.-time curve [AUC]) occurred on days 1, 14, 15, 28, and 29. Additional predose samples (Ctrough) were evaluated on days 7, 21, and 35. Laboratory and safety parameters were also evaluated. Results. The pharmacokinetics of Gengraf (Cmax, Tmax, Ctrough, and AUC) were indistinguishable from the Neoral values in stable renal allograft recipients. The bioequivalent capsules were interchangeable with respect to Cmax, Ctrough, and AUC at steady state and also on conversion from one capsule formulation to the other. The 90% confidence intervals (CI) for the Gengraf versus Neoral comparison at steady state (day 28 vs. day 14) were 0.95 to 1.03 for AUC and 0.92 to 1.04 for Cmax. Trough concentrations remained consistent throughout the study, with no need for dosage adjustment in any of the subjects. Gengraf is well tolerated, with an excellent safety profile, comparable to the safety profile of Neoral. Conclusions. The pharmacokinetics of Gengraf are equivalent and indistinguishable from those of Neoral. Gengraf is well tolerated and interchangeable with Neoral in stable renal transplant recipients.

Original languageEnglish (US)
Pages (from-to)1013-1017
Number of pages5
Issue number7
StatePublished - Oct 15 2002


Dive into the research topics of 'Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation'. Together they form a unique fingerprint.

Cite this